patient number the making Oxbryta. health an new three are: Jeff, These you care and we demand, Oxbryta, progress Thank which you, underlying Oxbryta, to for prescriptions progress. provide captures that informs will access everyone. update providers on coverage, which will further into the I environment are which speaks insight of for good adoption metrics key the prescribing payer our afternoon, and give on metrics
during There in quarter early prescriptions. Delta the XXX the approximately new new the variant of impact quarter, the holidays. were prescriptions First, reflecting and the
have less During be as to Specific engagements and to and levels, January, though field our pleased am the to QX, Omicron, dynamics with demand fewer and our access teams we continues improved patients recently adapt and to saw there an to between between interactions have environment, QX. providers compared in and infections changing as declined. compared providers team how continued impact to pre-pandemic I
a predictive visits, not believe to programs we quarter. new We sustain returning health have of in key potential, the incrementally brand yet that growth a As growth our to believe the a new result, have improvements leading we quarter levels, these indicators initiated in about prescriptions adherence. but remain we return and and improvement first patients' are are drive industry increase will the fourth and compared wide in indicators, Oxbryta's seen to pre-pandemic optimistic growth prescriptions, care new to meaningful to
new This the in most by extension of represents One significant new of mid-December. formulation label opportunities pediatric States. is patients the approved in total the the FDA XX% and United approximately the
prevent damage. new to the great to address start children allows Importantly, be young further a years pride help the oral disease opportunity liquid, their me age, down in once-daily is suitable have providers treat children. Oxbryta dispersed early potentially to health dosage to which form to to of care It for X and gives
teams, materials the train approval, Following the the to formulation our new quickly distribution into our update channel. get we FDA and work
from sickle the sales we XX% prescribers prescribers XXX learnings by treatment secure than disease on on team speaks formulation age our place from. payers younger in health can around administering team them In addition with to key adults, the most our aged that the live that educate This target younger who and the launch covered were as XX January, the geographies starting treated the current around to on indicates that label, of we children. of The strong in increases years. new kids following who to our XX%. that group cell the this with increases XX% is of is of is One it is already surveys several are X launch to last the this expansion to expanded position the be with positives care mid-January specialty and Xx processes Drilling the engaging perspective, is two-thirds around two-thirds we've providers already for This approved our around to down, working from in with are had label the pediatric engage. data illustrated which center of aware and with leverage by by list people, to more being the of another treated Oxbryta Viewed force. that the our likely feedback hematologist positive. among to sickle for disease new to our been are And early which more now primary are them compared more efficient a a cell the was of coverage. focus has who teams. know for from pediatric early providers model train and for
pleased launch. weeks are the broad awareness first in this achieve that of we few We
seamlessly the to patients already our pediatric younger We we are updated providers and with states. some prescriptions, early launch, pediatric on traction writing across Oxbryta Oxbryta DTC seeing starting campaign their To support and family and website. added many patient a our
prescriptions, November target patients providers. audience pull-through impact we its and investments incremental campaign new to in made is it to to exceeding reaching too in expand into care reach are measure While and the health how still early translates our
by impressions We audiences. tactics our other are leveraging zip geo code that on our segmentation target help and focus
disease the fundamental Oxbryta As these a education. campaign, result, cell cell pathophysiology, initiating sickle of is we XX launched of therapy. the achieved new sickle on months root understanding cause fundamentals campaign, conveying first the on of in focused providers DTC million complement focus we for and and patients sessions to Understanding education to of value a virtual our of and To X.X In on we critical the disease. the million series X continue unique impressions December, viewers. approximately
on we progress educating providers improving reducing and the new hemoglobin. hemolysis. on low of conversions. are delivery we're make oxygen fourth potential impact to patients importance the And In continue also educating quarter, the of We prescription improving
shows We patients are impressive our medicine and of program times leading good utilization adjudication to CoverMyMeds data getting rates, seeing QX ultimately turnaround faster. on and
we two range to that end During to Oxbryta persistence features see be some continued previously are restart. within of quarter, quarter hub. source the and support prior the patient the solutions new we or the and continuing for our year, analogs. therapy discontinued launched which compliance GBT of includes patient Around And patients adherence,
newsletters journey and the the will to ongoing First, email on it how time program. information by provided hub and access send now use a adherence provide patient's and the to support nurse
now mobile opt-in the patients receive to and see tactics can Second, discontinuations. increase engagement to messaging to with support We hope these hub. new engagement reduce
the Our fundamentals research strong continues also support Oxbryta. to market of
provider VOCs, half attended hospitalization. motivate we indicated for than and Over new health significantly this prescribers surveyed data said evidence non-prescribers ASH, the the prescribe. usage world more half conference, this will XX% surveyed of care call who and that on data Oxbryta's of post it their will transfusions example, them real current to increase For that
disease built by patients, Omicron of were with to less and variant. our terms shows January, that comfortable COVID, or telemedicine. in caregivers patients sickle delaying the many habits shifting appointments interrupted market seeking research care, feeling In reported treatment cell significantly their Many patients including
use, a that range BOC Looking and as polymerization health long-term of leads broad prescribers and addressing are burden, care my provider at Oxbryta to we patient such penetration. characteristics to increasingly second recognizing continue health, metric the baseline me hemoglobin suggesting see of which importance
both the we long-term positive by When a being is nearly new trend variant since breakdown we the XXX prescriptions health virtual the added meetings we of specialists lingering in-person and which for access to launch. bringing continue backdrop, our the writers, trajectory of launch. health to look many compared the QX prescribers total team to instead. on to leverage impact care the believe In providers quarter, interactions number X,XXX total to had due at our inconsistent about holidays still see tools the ecosystem. During written this in decreased non-specialists, the care Against and with had cases, and we quarter, Delta to of
Turning coverage. to payer
We continue coverage. to have payer broad
older access the United the population making and it covered For and and Oxbryta. having receive to with States our of in XX easier than XX% prescribe physicians lives is to patients on for patient more focus
team is addition, engaging In the payers to our label. approved with by them Oxbryta's the launch pediatric supporting educate of on expansion
payers. few are We nature. of with process prescriptions prior physicians in administrative by did for and through authorization talk group we these the positive, now will have we coverage XX been covered majority the believe many achieve have the patients seeing We in denials been the already than population. the faster our for that, about broad And adult adolescent can with Kim pipeline. age to X mid-XXXX, developments and with The
